From Iceland's woes, an $8B Actavis deal?

If Iceland's financial crisis was an earthquake, then this is a major aftershock: Actavis Group, one of the world's biggest generics makers, may go on the block for as much as $8 billion. Actavis is 80 percent-owned by Icelandic billionaire Thor Bjorgolfsson's private equity firm Novator. And Bjorgolfsson saw a big portion of his wealth go down the drain when Landsbanki Islands collapsed earlier this month.

Actavis had already hired Merrill Lynch to sift through its various options: sale, takeover, merger or public stock listing. Sources are now telling the Wall Street Journal that Bjorgolfsson's bank-related pain may push him to do a deal. A Novator spokesman said Actavis shareholders aren't looking to do a hasty deal, however. Any sale or merger wouldn't happen before next year, he said.

The global financial crisis could impede potential buyers, however. With companies strapped for credit, the M&A market has slowed considerably.

- read the WSJ article

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.